Exercise for Type 2 Diabetes

(ACELERATE-P Trial)

Overseen By Recruitment Department

Age: 18 - 65

Sex: Any

Trial Phase: Academic

Sponsor: AdventHealth Translational Research Institute

Must not be taking: Insulin, Incretin mimetics, Thiazolidinediones

Disqualifiers: Hypertension, Cancer, Smoking, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

12 Participants Needed

Trial Summary

What is the purpose of this trial?

The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and hepatic steatosis (fatty liver).

Research Team

Justine Mucinski, PhD

Principal Investigator

AdventHealth

Eligibility Criteria

This trial is for individuals with Type 2 Diabetes, particularly those who may also have fatty liver disease. Participants should be able to perform physical exercise and undergo body scans like DEXA and MRI.

Inclusion Criteria

I have signed a consent form to participate.

Lean, healthy controls: Normal liver fat (FibroScan CAP <249dB/m, <5.6% liver fat based on MRI)

I am willing and available to follow the study rules for its entire duration.

Exclusion Criteria

I have type 2 diabetes and a liver fat level of 5.6% or higher, and I am currently taking beta-blockers.

Individuals with T2D and elevated liver fat ≥5.6%: Alcohol consumption above specified limits

I am a healthy woman who is post- or peri-menopausal.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Exercise Intervention

Participants undergo exercise sessions to study the effects on endogenous glucose production

2 weeks

Multiple sessions (in-person)

Follow-up

Participants are monitored for safety and effectiveness after exercise intervention

2-4 weeks

Treatment Details

Interventions

• Acute Exercise

Trial Overview The study is examining how acute exercise affects the liver's glucose production in people with Type 2 Diabetes, which could influence treatment strategies for glycemic control and fatty liver.

Participant Groups

Group I: Lean, healthy controls Experimental Treatment 3 Interventions

Control group.

Group II: Individuals with T2D and hepatic steatosis Experimental Treatment 3 Interventions

T2D group.

Who Is Running the Clinical Trial?

AdventHealth Translational Research Institute

Lead Sponsor

Trials

51

Recruited

5,900+